925
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Reappraisal of Trifluperidol Against Nsp3 As a Potential Therapeutic for Novel COVID-19: A Molecular Docking and Dynamics Study

&
Pages 491-506 | Received 27 Oct 2020, Accepted 14 Jun 2021, Published online: 13 Jul 2021

References

  • Zheng J . SARS-CoV-2: an emerging coronavirus that causes a global threat. Int. J. Biol. Sci., 16(10), 1678–1685 (2020).
  • Huang C , WangY, LiXet al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497–506 (2020).
  • Wu F , ZhaoS, YuBet al. A new coronavirus associated with human respiratory disease in China. Nature, 579(7798), 265–269 (2020).
  • Cui J , LiF, ShiZ-L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol., 17(3), 181–192 (2019).
  • Baez-Santos YM , StJohn SE, MesecarAD. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res., 115, 21–38 (2015).
  • Lee HJ , ShiehCK, GorbalenyaAEet al. The complete sequence (22 kilobases) of murine coronavirus gene 1 encoding the putative proteases and RNA polymerase. Virology, 180(2), 567–582 (1991).
  • Saikatendu KS , JosephJS, SubramanianVet al. Structural basis of severe acute respiratory syndrome coronavirus ADP-ribose-1′-phosphate dephosphorylation by a conserved domain of nsP3. Structure, 13(11), 1665–1675 (2005).
  • Grunewald ME , ChenY, KunyCet al. The coronavirus macrodomain is required to prevent PARP-mediated inhibition of virus replication and enhancement of IFN expression. PLoS Pathog., 15(5), e1007756 (2019).
  • Kuri T , ErikssonKK, PuticsAet al. The ADP-ribose-1′-monophosphatase domains of SARS-coronavirus and human coronavirus 229E mediate resistance to antiviral interferon responses. J. Gen. Virol., 92, 1899–1905 (2011).
  • Michalska K , KimY, JedrzejczakRet al. Crystal structures of SARS-CoV-2 ADP-ribose phosphatase (ADRP): from the apo form to ligand complexes. bioRxiv doi: https://doi.org/10.1101/2020.05.14.096081 (2020) ( Epub ahead of print).
  • Bahadur Gurung A , AjmalAli M, LeeJ, AbulFarah M, MashayAl-Anazi K. Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme. J. King Saud Univ. Sci., 32(6), 2845–2853 (2020).
  • Padhi AK , ShuklaR, TripathiT. Rational design of the remdesivir binding site in the RNA-dependent RNA polymerase of SARS-CoV-2: implications for potential resistance. bioRxiv doi: 10.1101/2020.06.27.174896 (2020) (Epub ahead of print).
  • Rajendran V , KandasamyS, GuptaA, SelvarajJ, ShivanandappaKC. In silico identification of potential antivirals and molecular dynamics against SARS-CoV2 main protease and RBD of spike protein. ChemRxiv doi: 10.26434/chemrxiv.13181117.v1 (2020) (Epub ahead of print).
  • Pettersen EF , GoddardTD, HuangCCet al. UCSF Chimera – a visualization system for exploratory research and analysis. J. Comput. Chem., 25(13), 1605–1612 (2004).
  • Wishart DS , FeunangYD, GuoACet al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res., 46(D1), D1074–D1082 (2018).
  • Sterling T , IrwinJJ. ZINC 15 – ligand discovery for everyone. J. Chem. Inf. Model, 55(11), 2324–2337 (2015).
  • O’Boyle NM , BanckM, JamesCA, MorleyC, VandermeerschT, HutchisonGR. Open Babel: an open chemical toolbox. J. Cheminform., 3, 33 (2011).
  • Shukla R , MunjalNS, SinghTR. Identification of novel small molecules against GSK3β for Alzheimer’s disease using chemoinformatics approach. J. Mol. Graph. Model., 91, 91–104 (2019).
  • Pathak RK , GuptaA, ShuklaR, BaunthiyalM. Identification of new drug-like compounds from millets as Xanthine oxidoreductase inhibitors for treatment of Hyperuricemia: a molecular docking and simulation study. Comput. Biol. Chem., 76, 32–41 (2018).
  • Morris GM , HueyR, LindstromWet al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem., 30(16), 2785–2791 (2009).
  • Trott O , OlsonAJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem., 31(2), 455–461 (2009).
  • Shukla R , ShuklaH, KalitaP, TripathiT. Structural insights into natural compounds as inhibitors of Fasciola gigantica thioredoxin glutathione reductase. J. Cell. Biochem., 119(4), 3067–3080 (2018).
  • Shukla H , ShuklaR, SonkarA, TripathiT. Alterations in conformational topology and interaction dynamics caused by L418A mutation leads to activity loss of Mycobacterium tuberculosis isocitrate lyase. Biochem. Biophys. Res. Commun., 490(2), 276–282 (2017).
  • Rajendran V , ShuklaR, ShuklaH, TripathiT. Structure-function studies of the asparaginyl-tRNA synthetase from Fasciola gigantica: understanding the role of catalytic and non-catalytic domains. Biochem. J., 475(21), 3377–3391 (2018).
  • Shukla R , SinghTR. High-throughput screening of natural compounds and inhibition of a major therapeutic target HsGSK-3β for Alzheimer’s disease using computational approaches. J. Gen. Eng. Biotech., 19(1), 61 (2021).
  • Abraham MJ , MurtolaT, SchulzRet al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1–2, 19–25 (2015).
  • Schuittelkopf AW , van AaltenDMF. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr., 60(Pt 8), 1355–1363 (2004).
  • Oostenbrink C , VillaA, MarkAE, van GunsterenWF. A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6. J. Comput. Chem., 25(13), 1656–1676 (2004).
  • Chandra A , ChaudharyM, QamarI, SinghN, NainV. In silico identification and validation of natural antiviral compounds as potential inhibitors of SARS-CoV-2 methyltransferase. J. Biomol. Struct. Dyn.1–11 (2021).
  • Chandra A , GurjarV, QamarI, SinghN. Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19. J. Biomol. Struct. Dyn.1–11 (2020).
  • Pettersen EF , GoddardTD, HuangCCet al. UCSF Chimera – a visualization system for exploratory research and analysis. J. Comput. Chem., 25(13), 1605–1612 (2004).
  • Humphrey W , DalkeA, SchultenK. VMD: visual molecular dynamics. J. Mol. Graph., 14(1), 33–3827–28 (1996).
  • Kumari R , KumarR, LynnA. g_mmpbsa – a GROMACS tool for high-throughput MM-PBSA calculations. J. Chem. Inf. Model, 54(7), 1951–1962 (2014).
  • Debnath P , DebnathB, BhaumikS, DebnathS. In silico identification of potential inhibitors of ADP-ribose phosphatase of SARS-CoV-2 nsP3 by combining e-pharmacophore- and receptor-based virtual screening of database. ChemistrySelect, 5(30), 9388–9398 (2020).
  • Lehrer S , RheinsteinPH. SARS-CoV-2 orf1b gene sequence in the NTNG1 gene on human chromosome 1. In Vivo, 34(Suppl. 3), 1629–1632 (2020).
  • Mitra D , VermaD, MahakurBet al. Molecular docking and simulation studies of natural compounds of Vitex negundo L. against papain-like protease (PLpro) of SARS CoV-2 (coronavirus) to conquer the pandemic situation in the world. J. Biomol. Struct. Dyn.18–1 (2020).
  • Armstrong LA , LangeSM, de CesareVet al. Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies. bioRxiv doi: https://doi.org/10.1101/2020.12.09.417741 (2020) (Epub ahead of print).
  • Shim SS , GrantER, SinghS, GallagherMJ, LynchDR. Actions of butyrophenones and other antipsychotic agents at NMDA receptors: relationship with clinical effects and structural considerations. Neurochem. Int., 34(2), 167–175 (1999).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.